Related Experiment Video
Updated: May 24, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Pathogenesis and management of nasal polyposis in cystic fibrosis
Jochen G Mainz1, Assen Koitschev
1Cystic Fibrosis Center, Department of Paediatrics, Paediatric Pulmonology, Jena University Hospital, Jena, Germany. jochen.mainz@med.uni-jena.de
Insights
Cystic fibrosis (CF) patients often develop nasal polyposis (NP), a condition linked to defective ion transport and inflammation. Current treatments lack standardization and require more evidence from clinical trials.
Area of Science:
- Otorhinolaryngology
- Pulmonology
- Genetics
Background:
- Nasal polyposis (NP) affects up to 50% of cystic fibrosis (CF) patients, a significantly higher prevalence than in non-CF children.
- The exact pathogenetic factors for NP in CF remain unclear, though defective epithelial ion transport and impaired mucociliary clearance are implicated.
- CF-associated NP involves chronic inflammation dominated by neutrophils and pathogen colonization due to viscous secretions.
Purpose of the Study:
- To review the current understanding of cystic fibrosis-associated nasal polyposis (CF-NP) pathogenesis.
- To discuss existing and potential treatment modalities for CF-NP.
- To highlight the need for standardized, evidence-based treatment strategies and clinical trials.
Main Methods:
- Literature review of pathogenetic factors in NP and CF.
- Analysis of current treatment approaches for CF-NP, including conservative and surgical options.
- Evaluation of the role of topical steroids and CF-specific therapies.
Main Results:
- Defective epithelial ion transport is a key factor in CF, leading to viscous secretions that impair mucociliary clearance and promote inflammation.
- While topical steroids are standard for non-CF NP, their efficacy in neutrophilic CF-NP is debated.
- Existing treatments for CF-NP lack standardization and require further evaluation through controlled clinical trials.
Conclusions:
- CF-NP is a complex condition requiring further research into its pathogenesis.
- Current treatment strategies for CF-NP are diverse but lack robust evidence of efficacy.
- Interdisciplinary networks and controlled clinical trials are essential for developing standardized and effective treatments for CF-NP.
Abstract:
Beginning in preschool age, during their lives, up to 50% of cystic fibrosis (CF) patients experience obstructing nasal polyposis (NP), which is rare in non-CF children. Pathogenetic factors of NP in general and especially in CF are still obscure. However, defective epithelial ion transport from mucosal glands plays a central role in CF, and viscous secretions impair mucociliary clearance, promoting chronic pathogen colonization and neutrophil-dominated chronic inflammation. Presently, CF-NP is not curable but can be clinically stabilized, though the large variety of proposed treatment modalities indicates a lack of standardization and of evidence of treatment efficacy. When conservative measures are exhausted, surgical intervention combining individually adapted endoscopic sinus surgery and supportive conservative treatment is performed. Topical steroids, approved as the gold standard for non-CF NP, may be beneficial, but they are discussed to be less effective in neutrophilic inflammation, and CF-specific antimicrobial and mucolytic therapy, as is true of all treatment modalities, urgently requires evaluation by controlled clinical trials within interdisciplinary networks.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment

